Tamiflu is a brand-name antiviral medication that contains Oseltamivir Phosphate as its active component. It belongs to the antivirals class and is formulated as a pill (capsule) available in a 75 mg strength. In Hong Kong, Tamiflu is a prescription-only medicine regulated by the Department of Health and is approved for the treatment and prevention of influenza A and B infections. The product is marketed worldwide by Roche.
Oseltamivir is a neuraminidase inhibitor. The influenza virus carries an enzyme called neuraminidase on its surface, which helps newly formed viral particles leave infected cells and spread to other cells in the respiratory tract. By blocking neuraminidase, Tamiflu prevents this release, limiting the virus’s ability to replicate and reducing the severity and duration of flu symptoms.
Oseltamivir is administered as a prodrug; after oral absorption, it is rapidly converted by liver esterases into the active metabolite oseltamivir carboxylate, which is responsible for the neuraminidase-inhibiting activity.
Tamiflu is FDA- and EMA-approved, and likewise registered with Hong Kong’s Department of Health, for the following indications:
The medication is most effective when started as early as possible after flu symptoms appear. It is not indicated for severe, hospitalized influenza cases where intravenous antivirals (e.g., peramivir) may be preferred.
These symptoms usually resolve without medical intervention. Taking the capsule with food or a small snack can reduce gastrointestinal upset.
If a patient is taking multiple medications, they should disclose all prescriptions, over-the-counter drugs, supplements, and herbal products to their healthcare provider.
Dose reductions must be prescribed by a qualified clinician.
This article provides educational information about Tamiflu and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Current clinical evidence does not support the use of oseltamivir for COVID-19. The medication is specific to influenza viruses, and prescribing it for COVID-19 should be avoided unless a co-infection with influenza is confirmed.
When initiated within 48 hours of symptom onset, many patients experience a reduction in fever within 24-48 hours, though individual response can vary.
Tamiflu is classified as a Category C medication in pregnancy; it should be used only when the potential benefit outweighs any possible risk. Discuss the decision with an obstetrician.
Take the missed dose as soon as you remember, unless it is close to the time of the next scheduled dose. Do not double the dose; continue with the regular once-daily schedule.
Tamiflu capsules can be opened and the powder mixed with a small amount of soft food or liquid, but only under the guidance of a pharmacist to ensure accurate dosing.
Taking Tamiflu does not interfere with the inactivated influenza vaccine. However, it may reduce the effectiveness of the live attenuated nasal spray vaccine, so concurrent use should be avoided.
Keep the medication in its original container, at room temperature, away from direct sunlight, and in a carry-on bag to avoid temperature extremes in checked luggage.
Prophylactic dosing (75 mg once daily) can prevent the onset of influenza in individuals exposed to the virus, especially those at high risk for severe disease.
Symptoms include swelling of the face, lips, tongue, or throat, difficulty breathing, and hives. Seek emergency medical care immediately if these occur.
